Allogeneic hematopoietic stem cell transplantation in a patient with HIV-negative recurrent plasmablastic lymphoma

A case report

Chunmeng Rong, MD\textsuperscript{a}, Lixia Sheng, PhD\textsuperscript{b}, An Wu, MD\textsuperscript{a}, Ye Sun, MD\textsuperscript{a}, Guifang Ouyang, PhD\textsuperscript{b,*}

Abstract

Introduction: No standard guideline has been established for the treatment of plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and show resistance to commonly used cytostatic drugs.

Patient concerns: We present the case of a 52-year-old HIV-negative man who presented with a mass at the left sternoclavicular joint. He had no significant comorbidities and no latent immunosuppression.

Diagnosis: The largest lymph node measured was 36 × 19 mm. An excisional biopsy showed diffuse proliferation of large lymphoid cells which were positive for CD38 and CD138, but negative for CD20. He was diagnosed with stage IV PBL with a low IPI.

Interventions: The patient was treated with four cycles of induction therapy with bortezomib, epirubicin and dexamethasone. He achieved complete remission. But 3 months after receiving consolidated autologous hematopoietic stem cell transplantation, he relapsed. Allogeneic hematopoietic stem cell transplantation was performed on the patient.

Outcomes: The patient achieved remission again and there were no serious complications after allogeneic hematopoietic stem cell transplantation. This patient was followed up once every three months, and to date, he has been disease-free for more than 4 years.

Conclusion: The survival of recurrent PBL after autologous hematopoietic stem cell transplantation is very poor. Salvage allogeneic hematopoietic stem cell transplantation may bring long-term survival opportunities for those patients. Further clinical studies are needed to explore the role of allogeneic hematopoietic stem cell transplantation in refractory and recurrent PBL.

Abbreviations: allo-HSCT = allogeneic hematopoietic stem cell transplantation, ASCT = autologous hematopoietic stem cell transplantation, CHOP = cyclophosphamide, doxorubicin, vincristine and prednisone, CR = complete response, CT = computed tomography, DLBCL = diffuse large B-cell lymphoma, EBV-DNA = Epstein-Barr virus DNA, GVHD = graft-versus-host disease, HHV-8 = Human herpes virus 8, HIV = human immunodeficiency virus, IPI = International Prognostic Index, MNC = mononuclear cell, OS = overall survival, PBL = plasmablastic lymphoma, PBSC = peripheral blood stem cell, PET-CT = positron emission tomography–computed tomography, PR = partial response.

Keywords: allogeneic hematopoietic stem cell transplantation, autologous stem cell transplantation, HIV-negative, plasmablastic lymphoma, relapsed
1. Introduction
Plasmablastic lymphoma (PBL) is a rare and highly aggressive subtype of diffuse large B-cell lymphoma (DLBCL), characterized by plasma cell antigen differentiation. It was initially described in the setting of human immunodeficiency virus (HIV) infection, but it was also been reported in HIV-negative patients. There is no consensus on the standard of care for PBL. The role of intensification of induction chemotherapy is controversial. And novel agents, bortezomib and lenalidomide, have shown some effectiveness in relapsed cases and may have a relatively important role in frontline treatment. The use of autologous stem cell transplantation (ASCT) possibly improves outcomes when used as a consolidation or salvage therapy and may lead to better results than chemotherapy, but the available data remain sparse. The literatures on allogeneic hematopoietic stem cell transplantation (allo-HSCT) treatment for PBL are quite rare compared to ASCT. And given its rarity, most of the data available rely on case reports and case series. Patients with PBL have a poor prognosis, with median survival times shorter than 2 years. To the best of our knowledge, the survival of recurrent PBL is worse. Here, we report a case of HIV-negative PBL in a patient who had recurrence after ASCT, but achieved and maintained complete remission for 4-years after salvage allo-HSCT.

2. Case presentation
The patient was a 52-year-old man who presented in September 2015 with a mass at left sternoclavicular joint without any systemic symptoms. He had no significant comorbidities and no latent immunosuppression. Ultrasonography of lymph nodes indicated multiple lymph node enlargement in the neck, and multiple hypoechoic areas were seen above the left clavicle, the largest of which was 36 × 19 mm. A total body computed tomography (CT) scan showed that soft tissue mass shadows were seen around the left sternoclavicular joint and local cortical absorptions were present. Further investigations with fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) scan confirmed hypermetabolic mass appeared in several places of the body which was considered plasma cell infiltration. An excisional biopsy showed diffuse proliferation of large lymphoid cells (Fig. 1). Immuno-staining of the neoplastic cells showed negative for CD20, CD5, CD30, EREB, MPO, CD117 and Bcl-6, whereas it was positive for CD38, CD138, CD10, CD79a and Bcl-2 (Figs. 2–5). The Ki-67 proliferation index was 95% (Fig. 6). Biopsy of the iliac crest showed no marrow involvement. According to the above analysis, International Prognostic Index (IPI) scores were 2, the patient was diagnosed with stage IV PBL with a low IPI.

In addition, laboratory data were as following: Blood routine examination indicated that the white blood cells were 8.1 × 10⁹/L, the hemoglobin was 146 g/L and the platelets were 267 × 10⁹/L. Erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase, β2 microglobulin, serum proteins and immunoglobulin levels were all within normal ranges. Immunofixation electrophoresis showed no monoclonal component. Human herpes virus 8 (HHV-8) and Epstein-Barr virus DNA (EBV-DNA) were negative. Besides, serology for HIV was also negative.

From September to December 2015, the patient received 4 cycles of PAD chemotherapy regimens: bortezomib was given at...
the dose of 2.4 mg/day on day 1, 4, 8, 11, epirubicin at the dose of 20 mg/day on days 1–3, and dexamethasone at the dose of 40 mg/day on days 1–4 and 8–11 of each 28-day cycle. Repeat PET/CT following 4 cycles of chemotherapy showed no abnormal fluorodeoxyglucose metabolic foci and enlarged lymph nodes, thus being compatible with a complete response (CR).

Later on, peripheral blood stem cell (PBSC) mobilization was achieved by high-dose cyclophosphamide (2g, day 1–3), etoposide (300mg, day 1–3) and granulocyte colony-stimulating factor (G-CSF), and leukapheresis products containing a total of mononuclear cell (MNC) $9.78 \times 10^8$/kg and CD34+ cells $6.9 \times 10^6$/kg were collected. In April 2016, the patient received autologous hematopoietic stem cell transplantation as consolidation therapy. The conditioning regimens were melphalan (200 mg/m² -2d) and bortezomib (1.75 mg -6, -3, +1, +4), and a total of $9.78 \times 10^8$/kg MNC and $6.9 \times 10^6$/kg CD34+ cells PBSC were reinfused. Platelets and white blood cells were recovered at 10 and 11 days after transplantation, respectively. The CT scan performed 1 month after ASCT confirmed a CR.

However, 3 months after ASCT, CT showed a new lesion appeared in the second rib on the right side, which was considered as relapse. After full assessment, the patient underwent HLA half-matched allo-HSCT in September 2016. The conditioning regimen was modified BuCy+ATG (cytarabine 3.5 g -10, -9; busulfan 51.6mg Q6h -8, -7, -6; cyclophosphamide 3g -5, -4; MECCNU 450mg -3; antithymocyte globulin 2.5mg/Kg -5, -4, -3, -2), and the scheme for prevention of graft-versus-host disease (GVHD) was cyclosporin, mycophenolate mofetil and short-term methotrexate. The patient developed pulmonary fungal infection 20 days after allo-HSCT and took a turn for the better after treatment with voriconazole injection and voriconazole tablets. Unfortunately, the patient developed severe hemorrhagic cystitis 20 days later, but fortunately the condition improved after symptomatic treatment. There has been no evidence of acute or chronic GVHD. The patient achieved sustained complete donor engraftment as short tandem repeat monitoring was performed every three months after transplantation. A CR was metabolically and clinically confirmed by PET/CT scan after allo-HSCT. The patient is now healthy and in CR for 4 years after allo-HSCT.

3. Discussed

PBL is a distinct variant of diffuse large B-cell lymphoma initially described in HIV-positive patients. Nevertheless, PBL has also been described in HIV-negative individuals, particularly in
association with potential immunosuppression such as after solid organ or bone marrow transplantation or with autoimmune disorders and malignancies.\[^{6–11}\]\(^{6–11}\) HIV-negative PBL, in comparison with HIV-positive PBL, occurs in older patients, with less frequent involvement of oral mucosa or bone marrow and less frequently stages III-IV.\[^{12,13}\]\(^{12,13}\) A review of 114 HIV-negative patients with PBL, by Liu et al\[^{12}\]\(^{12}\) demonstrated that immunosuppression, MYC gene rearrangement, high-risk international prognostic index, and EBV negativity were poor prognostic factors. And the overall survival (OS) is between 9 and 19 months in HIV-negative patients.\[^{12}\]\(^{12}\) Similarly, a systematic review on 76 HIV-negative PBL patients showed median OS of 9 months with 2-year OS rate of 10%.\[^{13}\]\(^{13}\)

Given its rarity and peculiar features, there is no standard of care for PBL and the treatment remains a challenge.\[^{11}\]\(^{11}\) The use of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) and CHOP-like regimens are considered inadequate therapy, resulting short remission period\[^{13,11}\]\(^{13,11}\) so the NCCN guidelines recommend more intensive regimens,\[^{14}\]\(^{14}\) including etoposide, vincristine and doxorubicin with bolus of cyclophosphamide and prednison (EPOCH),\[^{15}\]\(^{15}\) cyclophosphamide, vincristine, doxorubicin, methotrexate alternating with ifosfamide, etoposide, cytarabine,\[^{16}\]\(^{16}\) or hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with methotrexate and cytarabine.\[^{17}\]\(^{17}\) The benefit of ASCT in patients with PBL is not quite clear based on the limited data available. In a single institution report of 9 consecutive HIV-negative PBL patients, 7 patients achieved CR and 1 patient achieved partial response (PR) after chemotherapy.\[^{19}\]\(^{19}\) Four patients underwent consolidation with ASCT in first complete remission, and 2 of these patients were alive at median follow-up of 23.9 months. The third patient had disease recurrence at 14 months and the fourth patient had disease recurrence at 2 months after ASCT.\[^{19}\]\(^{19}\) Moffitt Cancer Center presented the experience of two HIV-negative patients with PBL in PR that underwent an ASCT, and two patients survived 6 and 12 months.\[^{12}\]\(^{12}\)

Given the low efficacy of the standard therapy, and the poor outcome of these patients, there is a need to move toward new therapeutic strategies by incorporating new agents. Bortezomib is the most reported new drug for PBL and has been used as a single dose or in combination. Koji et al\[^{18}\]\(^{18}\) show the bortezomib and lenalidomide-based treatment was tolerated and the patient was continued with a PR for over 2 years. Bortezomib and lenalidomide have a certain therapeutic effect, and are mostly used in patients with refractory recurrence.\[^{18,19}\]\(^{18,19}\) There are few case reports showing single-agent lenalidomide or combination with other chemotherapeutic drug in refractory PBL.\[^{19–20}\]\(^{19–20}\) A dramatic response to Brentuximab has been reported in a single case, but the patient died shortly due to previous disease disabilities.\[^{21}\]\(^{21}\) A plasmablastic microlymphoma arising in HHV8-associated multicentric Castleman disease in an HIV-negative patient that showed a clinical response to siltuximab, an anti-IL6 antibody.\[^{24}\]\(^{24}\) The use of rituximab, a chimeric anti-CD20 monoclonal antibody, is not currently a therapeutic standard because the lack of CD20 expression by PBL cells, but combined with chemotherapy it could improve remission rates.\[^{2,25}\]\(^{2,25}\) Clinical trials with novel immunotherapeutic agents and other drugs targeting some genes involved in the activation of Nuclear factor kappa B pathways, some of which are already ongoing, may show promising results.\[^{18}\]\(^{18}\)

The literature on allo-HSCT in PBL is limited compared with ASCT. Only few cases of allo-HSCT for PBL were reported, much less for recurrence PBL. Hamadani\[^{26}\]\(^{26}\) reported one patient with PBL in CR2 who underwent a reduced-intensity allogeneic stem cell transplantation, and was alive 2 years after transplantation. Liu et al\[^{10}\]\(^{10}\) reported one patient who had disease recurrence at 14 months after ASCT was treated with allo-HSCT. Despite consolidation with allo-HSCT, disease recurred 5 months after, and the patient died. In general, the efficacy of allo-HSCT in the treatment of HIV-negative PBL patients is still not ideal and the survival of recurrent PBL after allo-HSCT is very poor.

In our case, the patient had recurrence after consolidated ASCT. Then, he underwent the salvage allo-HSCT from his daughter and achieved good curative effect. The patient was in long-term complete remission and he is alive now. It may be attributed to his younger age, low IPI score and early allo-HSCT treatment after relapse. As far as we know, this is the first case of such a long survival time after allo-HSCT. For young relapsed patients with PBL, allo-HSCT may bring long-term survival opportunities. Due to the rarity of the disease, it is not feasible to carry out large-scale clinical trials. The evaluation of allogeneic hematopoietic stem cell transplantation in PBL patients requires more accumulation and sharing of clinical experience.

**Author contributions**

**Data curation:** An Wu, Ye Sun.

**Funding acquisition:** Guifang Ouyang, Lixia Sheng.

**Methodology:** Lixia Sheng.

**Writing – original draft:** Chunmeng Rong.

**Writing – review & editing:** Chunmeng Rong.

**References**

[1] Li YJ, Li JW, Chen KL, et al. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. Blood Res 2020;55:49–56.

[2] Al-Malki MM, Castillo JJ, Sloan JM, et al. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant 2014;20:1877–84.

[3] Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer 2018;8:63–70.

[4] Fernandez-Alvarez R, Sancho JM, Ribera JM. Plasmablastic lymphoma. Med Clin 2016;147:399–404.

[5] Castillo JJ, Furman M, Beltran BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012;118:5270–7.

[6] Noy A, Lensing SY, Moore PC, et al. Plasmablastic lymphoma is treatable in the HAART era. A 10-year retrospective by the AIDS Malignancy Consortium. Leuk Lymphoma 57 2016;1731–4.

[7] Delecluse HJAL, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413–20.

[8] Liu JJ, Zhang L, Ayala E, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leukemia Res 2011;35:1571–7.

[9] Borenstein J, Pezzella F, Gatter KC. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology 2007;51:774–7.

[10] Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010;51:2047–53.

[11] Castillo JJ, Bilos M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015;125:2322–30.

[12] Liu M, Liu B, Liu B, et al. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases. Oncol Rep 2015;33:1615–20.

[13] Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk 2011;11:185–9.
[14] Andrew D Zelenetz JSA, Ranjana H. Advani, C Babis Andreadis, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 2010;8:288–334.

[15] Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted epoch and rituximab in untreated diffuse large b-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717–24.

[16] Magrath IAM, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925–34.

[17] Cortes J, Thomas D, Ruos A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related burkitt lymphoma/leukemia. Cancer 2002;94:1492–9.

[18] Ando K, Imaizumi Y, Kobayashi Y, et al. Bortezomib- and lenalidomide-based treatment of refractory plasmablastic lymphoma. Oncol Res Treat 2020;43:112–6.

[19] Bibas M, Grisetti S, Alba L, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. Journal of clinical oncology 2010;28:e704–8.

[20] Carras S, Regny C, Peoc’h M, et al. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Leukemia & lymphoma 2015;56:2986–8.

[21] Michele Bibas SG, Lucia Alba, Giovanna Picchi, et al. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 2010;28:e704–8.

[22] Schmit JM, DeLaune J, Norkin M, et al. A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy. Oncol Res Treat 2017;40:46–8.

[23] Pretscher D, Kalisch A, Wilhelm M, et al. Refractory plasmablastic lymphoma—a review of treatment options beyond standard therapy. Ann Hematol 2017;96:967–70.

[24] Koenig G, Stevens TM, Peker D. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. Histopathology 2015;67:903–2.

[25] Koizumi Y, Uehira T, Ota Y, et al. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. Int J Hematol 2016;104:669–81.

[26] Hamadani M, Devine SM. Reduced-intensity conditioning allogeic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. Blood 2009;114:2364–8.